Recombinant Human MMP-2 Protein (Active)
| Code | Size | Price |
|---|
| PKSH031888-20ug | 20ug | £398.00 |
Quantity:
| PKSH031888-100ug | 100ug | £1,097.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Human
Regulatory Status: RUO
Application: Enzyme-Linked Immunosorbent Assay (ELISA)
Shipping:
This product is provided as lyophilized powder which is shipped with ice packs.
Storage:
Samples are stable for up to twelve months from date of receipt at -70°C. Store it under sterile conditions at -20°C to -80°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Further Information
Abbreviation:
MMP-2
Accession:
NP_004521.1
Activity:
1. Measured by its ability to cleave the fluorogenic peptide substrate Mca-PLGL-Dpa-AR-NH2 (AnaSpec, Catalog # 27076). The specific activity is > 1, 000 pmoles/min/ug.
2. Immobilized human MMP2 at 10 ug/mL (100 ul/well) can bind human TIMP2/Fc. The EC50 of human TIMP2/Fc is 0.02 ug/mL. (Activation description: The proenzyme needs to be activated by APMA for an activated form)
Background:
Matrix Metalloproteinase-2 (MMP-2) is an enzyme that degrades components of the extracellular matrix and thus plays a pivotal role in cell migration during physiological and pathological processes. MMP-2 expression is dependent on extracellular matrix metalloproteinase inducer (EMMPRIN); Her2/neu; growth factors; cytokines; and hormones. Pro-MMP-2 activation needs MT1-MMP and TIMP-2 contribution. MMP-2 is changed in distribution and increased in amount in the ventral cochlear nucleus after unilateral cochlear ablation. A low level of MMP-2 is linked to favorable prognosis in patients with a hormone receptor-negative tumor; usually associated with high risk. As a zymogen requiring proteolytic activation for catalytic activity; MMP-2 has been implicated broadly in the invasion and metastasis of many cancer model systems; including human breast cancer (HBC). Blocking MMP-2 secretion and activation during breast carcinoma development may decrease metastasis. The detection of active MMP-2 alone or the rate of pro-MMP-2 and active MMP-2 is considered a very sensitive indicator of cancer metastasis. Modulation of MMP-2 expression and activation through specific inhibitors and activators may thus provide a new mechanism for breast cancer treatment.
Endotoxin:
< 1.0 EU per ug of the protein as determined by the LAL method.
Expression Host:
HEK293 Cells
Formulation:
Lyophilized from sterile PBS, pH 7.4
Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.
Please refer to the specific buffer information in the printed manual.
Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.
Please refer to the specific buffer information in the printed manual.
Fusion tag:
None
ObservedMW:
72 kDa
Purity:
> 90 % as determined by reducing SDS-PAGE.
Sequence:
Met 1-Cys 660
Target Synonym:
72 kDa Type IV Collagenase;72 kDa Gelatinase;Gelatinase A;Matrix Metalloproteinase-2;MMP-2;TBE-1;MMP2;CLG4A;CLG4;MMP-II;MONA;TBE-1